Reduced Final Height Outcome in Congenital Adrenal Hyperplasia under Prednisone Treatment: Deceleration of Growth Velocity during Puberty
The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
CONTEXT: Normal to decreased final height (FH) has been reported in patients with congenital adrenal hyperplasia (CAH). OBJECTIVE: The objective was to determine FH outcome and influences of steroid treatment. METHODS: The effects of glucocorticoid treatment for classical CAH were retrospectively studied in 125 patients (77 females). Growth pattern, FH, and pubertal development were recorded. RESULTS: Corrected FH was in the lower range of genetic potential [females with simple virilizing (SV)-CAH, -0.6 +/- 1.0 sd score (SDS) vs. females with salt-wasting (SW)-CAH, -0.6 +/- 0.9 SDS; males with SV-CAH, -1.1 +/- 0.9 SDS vs. males with SW-CAH, -0.9 +/- 0.9 SDS]. Total pubertal growth was significantly reduced in comparison with a reference population (females with SV-CAH, 11.9 +/- 6.5 cm, and females with SW-CAH, 13.8 +/- 7.6 cm vs. reference 20.3 +/- 6.8 cm, P < 0.01; and males with SV-CAH, 15.4 +/- 6.6 cm, and males with SW-CAH, 18.5 +/- 6.9 cm vs. reference 28.2 +/- 8.2 cm, P < 0.01). Thirty-three patients had been treated with prednisone, which resulted in reduced FH compared with patients (n = 92) treated with hydrocortisone (-1.0 +/- 0.9 SDS vs.-0.6 +/- 0.9 SDS; P < 0.05). FH correlated negatively with hydrocortisone dose given at the start of puberty (r = -0.3; P < 0.05). Pubertal development started early in boys [9.8 +/- 2.3 yr (SV) and 10.6 +/- 1.9 yr (SW)] and was timely in girls [9.8 +/- 1.9 yr (SV) and 10.3 +/- 1.5 yr (SW), menarche at 13.3 +/- 1.7 yr (SV) and 13.7 +/- 1.5 yr (SV)]. CONCLUSION: Patients with CAH are able to achieve adequate FH with conventional therapy. Total pubertal growth is significantly decreased, and treatment with prednisone results in decreased FH. In addition to biochemical analysis, treatment should be adjusted to normal growth velocity, especially during puberty.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hydrocortisone is the preferred glucocorticoid in children with CAH owing to its short half-life and the fact that it has the lowest growth suppressing effect of available glucocorticoids24,28.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [28]
In the citing paper
“However, adult height correlates negatively with glucocorticoid dose during puberty, especially doses of hydrocortisone exceeding 17 mg/m2 per day28.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [28]
In the citing paper
“The adult height of patients with CAH correlates negatively with the dose of GC administered in early puberty; patients treated with ,20 mg of HC/m 2 per day at the start of puberty are significantly taller than those given higher HC doses (187).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [187]
In the citing paper
“During childhood, the preferred GC is HC because its short half-life minimizes the adverse side effects typical of longer-acting, more potent GCs, especially growth suppression (Table 2) (187).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [187]
Citations
Cites
RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST
GREULICH, W. W., & PYLE, S. I. (1959) · The American Journal Of The Medical Sciences · doi:10.1097/00000441-195909000-00030 · Cited by 5,585
Body mass index reference curves for the UK, 1990.
Cole, T. J., Freeman, J. V., & Preece, M. A. (1995) · Archives of Disease in Childhood · doi:10.1136/adc.73.1.25 · Cited by 2,047
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Prader, A., Largo, R. H., Molinari, L., & Issler, C. (1989) · PubMed · Cited by 814
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Self-citationMulaikal, R. M., Migeon, C. J., & Rock, J. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701223160402 · Cited by 361
Pubertal development in Swiss boys.
Rh, L., & Prader, A. (1983) · PubMed · Cited by 234
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Pubertal development in Swiss girls.
Largo, R. H., & Prader, A. (1983) · PubMed · Cited by 200
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“patients with CAH correlates negatively with the dose of GC administered in early puberty; patients treated with,20mg of HC/m(2) per day at the start of puberty are significantly taller than those given higher HC doses (187).”
BackgroundSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Adult Height in Patients with Congenital Adrenal Hyperplasia: A Systematic Review and Metaanalysis
Muthusamy, K., Elamin, M. B., Smushkin, G., Murad, M. H., Lampropulos, J. F., Elamin, K. B., Abu Elnour, N. O., Gallegos-Orozco, J. F., Fatourechi, M. M., Agrwal, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2616 · Cited by 182
Metadata
- Authors
- Bonfig, W., Bechtold, S., Schmidt, H., Knorr, D., & Schwarz, H. P.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Bonfig, Walter
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1635-1639
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160090915
- Cited by
- 167
- References
- 40
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 6 · 2019: 15 · 2018: 4 · 2017: 7 · 2016: 9 · 2015: 1 · 2014: 8 · 2013: 11 · 2012: 6
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, adult height, prednisone, cortisol, glucocorticoid therapy, growth rate, puberty, pubertal growth, simple virilizing CAH, salt-wasting CAH, menarche, growth hormone therapy, genetic potential, dose-response relationship, short stature, children and adolescents, sex differences, puberty timing
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Body Height, Breast, Child, Female, Growth, Hormones, Humans, Hydrocortisone, Male, Prednisone, Puberty, Retrospective Studies, Steroid 21-Hydroxylase, Testis, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.